Phase III clinical trials (SEQUOIA andCEDAR) were designed to compare 8- and 12-week intervals vs. monthlyinjections with ranibizumab; this may represent another breakthrough inanti-VEGF treatment for AMD. The gene discussed is VEGFA; the disease is age-related macular degeneration.